IQVIA Holdings Inc. $IQV Position Lessened by HF Advisory Group LLC

HF Advisory Group LLC lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 24.0% in the third quarter, HoldingsChannel reports. The firm owned 8,174 shares of the medical research company’s stock after selling 2,584 shares during the quarter. HF Advisory Group LLC’s holdings in IQVIA were worth $1,553,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in IQV. GAMMA Investing LLC boosted its holdings in shares of IQVIA by 57.3% during the third quarter. GAMMA Investing LLC now owns 3,414 shares of the medical research company’s stock valued at $648,000 after acquiring an additional 1,244 shares during the period. Praxis Investment Management Inc. bought a new stake in IQVIA in the 3rd quarter valued at about $426,000. Osaic Holdings Inc. boosted its stake in IQVIA by 32.0% during the 2nd quarter. Osaic Holdings Inc. now owns 71,103 shares of the medical research company’s stock valued at $11,233,000 after purchasing an additional 17,217 shares during the period. Orion Porfolio Solutions LLC grew its position in IQVIA by 7.0% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 19,552 shares of the medical research company’s stock worth $3,081,000 after purchasing an additional 1,282 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in shares of IQVIA in the second quarter valued at approximately $242,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This trade represents a 12.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Stifel Nicolaus increased their price objective on IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Hsbc Global Res raised IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. BMO Capital Markets started coverage on IQVIA in a report on Thursday, November 13th. They set an “outperform” rating and a $260.00 price target on the stock. Cowen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Monday, November 3rd. Finally, HSBC raised shares of IQVIA from a “hold” rating to a “buy” rating and raised their target price for the company from $195.00 to $235.00 in a research note on Thursday, October 9th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $243.59.

IQVIA Price Performance

NYSE:IQV opened at $223.71 on Tuesday. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The business’s 50-day moving average price is $217.39 and its 200 day moving average price is $190.61. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $234.29. The firm has a market cap of $38.10 billion, a P/E ratio of 30.69, a PEG ratio of 2.49 and a beta of 1.37.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. The company had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. IQVIA’s revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the company earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.